XML 55 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2015
Commitments and Contingencies [Abstract]  
Summary of milestone payment

Milestones Payments 
    
(1) when Company initiates a Phase 1 Clinical Trial of a licensed product $750,000 
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product  750,000 
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product  1,500,000 
(4) Biological License Application filing with U.S. FDA  1,750,000 
(5) First commercial sale  1,500,000 
(6) after the first $10,000,000 in net sales  1,500,000 
Schedule of future minimum obligations on the lease

 

For the year ending June 30, 2016 $135,385 
For the year ending June 30, 2017  28,004 
   163,389